Theratechnologies Inc. (THTX)

Market Cap	59.77M
Revenue (ttm)	57.85M
Net Income (ttm)	-13.33M
Shares Out	45.98M
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	55.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,303
Open	1.300
Previous Close	1.410
Day's Range	1.295 - 1.410
52-Week Range	0.880 - 4.320
Beta	1.78
Analysts	Buy
Price Target	18.67 (+1,224.11%)
Earnings Date	Apr 10, 2024

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: THTX

Financial Performance

In 2023, THTX's revenue was 81.76 million, an increase of 2.13% compared to the previous year's 80.06 million. Losses were -23.96 million, -49.28% less than in 2022.

Financial numbers in CAD

Analyst Forecast

According to 3 analysts, the average rating for THTX stock is "Buy." The 12-month stock price forecast is $18.67, which is an increase of 1,224.11% from the latest price.

Price Target

$18.67

(1,224.11% upside)

Analyst Consensus: Buy